AD-224
- Generic Name
- AD-224
A Study to Evaluate the Efficacy and Safety of AD-224
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-224CDrug: Placebo of AD-224BDrug: Placebo of AD-224ADrug: Placebo of AD-224C
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT06291207
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath